- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00688454
C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients
April 8, 2009 updated by: AstraZeneca
The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy.
This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
3392
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Statin-naive patients and unsuccessfully treated with other (non rosubastatin) statins patients
Description
Inclusion Criteria:
- Patients with hypercholesteremia who was never treated with statins before
- Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Pt with hypercholesteremia
Patients treated with CRESTOR because of hypercholesteremia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
LDL-Cholesterin, HDL-Cholesterin, Triglycerides, Total Cholesterin
Time Frame: 3 visits within 10 weeks
|
3 visits within 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tolerability of CRESTOR-therapy
Time Frame: 3 visits within 10 weeks
|
3 visits within 10 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2007
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
May 29, 2008
First Submitted That Met QC Criteria
June 2, 2008
First Posted (Estimate)
June 3, 2008
Study Record Updates
Last Update Posted (Estimate)
April 9, 2009
Last Update Submitted That Met QC Criteria
April 8, 2009
Last Verified
April 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-CCH-CRE-2007/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.